Researcher profile
Nir Barzilai, MD
TAME is the trial designed to make regulators treat aging as an indication. He is the strongest advocate for metformin as a geroprotector, which is exactly why his framing of the evidence is worth reading directly.
- Role
- Principal investigator of the TAME metformin trial
- Affiliation
- Albert Einstein College of Medicine, where he is Professor of Medicine and Genetics
- Topics
- Metformin · TAME · Trial design
- Their work
- Search PubMed
Why we quote Barzilai
TAME is the trial designed to make regulators treat aging as an indication. He is the strongest advocate for metformin as a geroprotector, which is exactly why his framing of the evidence is worth reading directly.
Nir Barzilai, MD is one of the researchers quoted here; the others quoted alongside Nir are listed with the same disclosures.
Where they stand, and who pays
Advocate rather than neutral party: he has spent a decade trying to fund this trial, and the trial has not reported efficacy results.
Stating this next to the quote rather than at the bottom of a disclosures page is the whole point. A concession made against a commercial interest is stronger evidence than a neutral summary; a claim made in line with one is weaker. You cannot weigh either without knowing which you are reading.
Everything we quote them saying
All 2 lines, verbatim, in the order they appear in the site's citation index. Each one links to the recording and to the page it is used on.
If you are young and a bodybuilder and the muscle is important for you, don't take metformin.
Used on Metformin Dosage for Longevity: Borrowed, Unproven Numbers
They were more obese and had more diseases to start, and still they had 17% lower mortality.
Used on Metformin for Longevity: What the Evidence Actually Supports
Pages this research informs
Each page below cites this researcher directly, so you can see the claim a quote supports in its full context.
The standing disclaimer
Nir Barzilai, MD has no relationship with Rapamycin.store and does not endorse anything on it.
- They have not reviewed this site or any page that quotes them.
- Quotes are used under fair dealing for criticism and review, each linked to its public recording so you can hear the full context.
- If a quote here misrepresents what was said, tell us and we will correct it. That correction goes to the front of the queue.
Researchers who want to set out a position in their own words, rather than be quoted, can offer an article of their own.
References
3 sources, all link-checked; oldest check
- Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. International Committee of Medical Journal Editors, updated 2025.The conflict-of-interest and authorship conventions this desk follows for a lay publication.Verified Sep 14, 2026
- PubMed. US National Library of Medicine, National Institutes of Health.The index every citation on this site is checked against before publication.Verified Sep 14, 2026
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Guyatt GH et al. BMJ 2008;336:924.The framework behind the strong / mixed / limited evidence grades used across this site.Verified Sep 14, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.